Takeda_Red_Logo_2021

Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years

Children Ages 2 to <12 Experienced 94.8% Fewer Hereditary Angioedema (HAE) Attacks During Treatment with TAKHZYRO Over the 52-Week Treatment...

Acumen-Research-and-Consulting-7

Growing Prevalence of Chronic and Undiagnosed Diseases Will Propel the Computer Aided Drug Discovery Market to Reach USD 7,232 Million By 2030 Report By Acumen Research and Consulting

Acumen Research and Consulting recently published report titled “Aided Drug Discovery Market Size, Share, Analysis Report and Region Forecast, 2022...

news_6

82% Of Internet Users in Countries With Some of the World’s Harshest Internet Censorship Regulations Expect the Need for Web Access Tools to Grow in the Next Year, Hola Research Reveals